Topics:

Juvenile Arthritis

Best of EULAR 2014

What you missed by not going to Paris this year, other than great wine and fresh croissants: Sex (and gout). Smoking (bacteria, and RA). Pain relief (and its importance to the success of RA medication). A virus (papilloma, and JIA). And yet more ...

Juvenile Arthritis

The background risk of cancer in JIA is at least double that in the general population. But a new review finds that such cases are rare, and not linked solely to biologics used to treat the condition.

Macrophage activation syndrome, a devastating complication of some rheumatic conditions, shows pathologic similarities to a rare hereditary condition. Genetic studies imply that their similarities may be more than coincidental.

A new international multicenter study of often-deadly macrophage activation syndrome in systemic JIA reveals key laboratory and clinical warning signs. Watch ferritin levels especially closely.

A new auto-injectable form of methotrexate offers 10 dosage options. Is this an important advantage for medication management and adherence over the four already available?

Three proposed standardized treatment plans may also aid research into managing newly-diagnosed polyarticular juvenile idiopathic arthritis.

(EULAR 2014) Analysis of 7-month results show few problems and great benefit for the Gardasil vaccine against human papilloma virus in girls or young women with juvenile arthritis.

(ACR Pediatrics 2014) Children growing into young adults with rheumatic diseases often fail to get the care they need, for numerous complicated reasons. The ACA could change all this, with implications for adult rheumatologists. Here, a brief look at the situation and some solutions.

Pages

Subscribe to Juvenile Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.